Imatinib

Overview

Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with an IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. Imatinib is an oral chemotherapy agent used to treat cancers. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | c-Kit

Product Information

• Catalog No.: B0046-463864
• CAS No.: 152459-95-5
• Molecular Formula: C29H31N7O
• Molecular Weight: 493.60
• Purity: >98%
• Storage: Store at -20°C
• Solubility: Soluble in DMSO (Slightly, Heated), Methanol (Slightly, Heated)

Source

Original product source